Altimmune (ALT) Expected to Announce Earnings on Thursday

Altimmune (NASDAQ:ALT - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Altimmune to post earnings of ($0.36) per share and revenue of $0.00 million for the quarter.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Stock Down 4.8 %

NASDAQ:ALT traded down $0.26 during mid-day trading on Tuesday, reaching $5.17. 1,046,100 shares of the company were exchanged, compared to its average volume of 2,847,904. Altimmune has a 12 month low of $3.55 and a 12 month high of $11.16. The company has a fifty day moving average of $5.15 and a 200 day moving average of $6.64. The stock has a market cap of $398.16 million, a PE ratio of -3.36 and a beta of 1.13.

Insider Activity at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on ALT shares. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. Stifel Nicolaus initiated coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target on the stock. Finally, William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.